Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition [0.03%]
骨转移数量对mHSPC患者的抗肿瘤效果的影响(CHAARTED定义的轴向 skeleton 排除在外)
Mike Wenzel,Lena Theissen,Carolin Siech et al.
Mike Wenzel et al.
Objective: Patient and treatment stratification for metastatic hormone-sensitive prostate cancer (mHSPC) is usually based on metastatic burden according to CHAARTED criteria, classifying high-volume disease as at least 4 ...
Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry [0.03%]
基于瑞士国家多中心前瞻性登记的前列腺癌 biopsy-to-treatment延误:疫情后的影响
Timon Winistoerfer,Simone Scuderi,Giorgio Gandaglia et al.
Timon Winistoerfer et al.
Background: Surgical delays increased during the COVID-19 pandemic. The effect of treatment delay in intermediate- and high-risk prostate cancer remains uncertain. We evaluated whether biopsy-to-surgery delay influences e...
Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis [0.03%]
恩fortumab vedotin单药治疗、恩fortumab vedotin联合派姆单抗和免疫检查点抑制剂新辅助治疗肌层浸润性膀胱癌:系统评价和meta分析
Shugo Yajima,Soichiro Yoshida,Naoki Imasato et al.
Shugo Yajima et al.
Comparative efficacy among neoadjuvant enfortumab vedotin (EV) monotherapy, EV plus pembrolizumab (EV+P), and immune checkpoint inhibitor (ICI)-based regimens for muscle-invasive bladder cancer (MIBC) is unclear, and we aimed to compare pat...
Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States [0.03%]
奥拉帕利单药治疗美国转移性去势抵抗性前列腺癌患者的现实临床结果、基因检测模式和治疗模式
Daniel J George,Furaha Kariburyo-Yay,Himani Aggarwal et al.
Daniel J George et al.
Introduction: The PROfound clinical trial showed that patients with metastatic castration-resistant prostate cancer (mCRPC) who harbored homologous recombination repair gene mutations (HRRm) benefited from receiving olapa...
Microsimulation modeling of alternate surveillance strategies in renal oncocytoma: Practical considerations for intervention [0.03%]
肾脏乳头状癌替代检测策略的微观模拟模型:干预的实际考虑因素
Daniel L Ranti,Gabriella T Seo,Siddharth Ghanta et al.
Daniel L Ranti et al.
Background: Use of renal mass biopsy (RMB) has increased, leading to more diagnoses of renal oncocytoma. Although benign, diagnostic uncertainty and the absence of clear size thresholds for intervention complicate managem...
Longitudinal utDNA dynamics predict recurrence risk in upper tract urothelial carcinoma: A prospective cohort study [0.03%]
纵向细胞免费DNA动力学预测上尿路尿路上皮癌复发风险:一项前瞻性队列研究
Wei Zuo,Qi Tang,Xuanjun Guo et al.
Wei Zuo et al.
Background and objective: Current surveillance of bladder recurrence for upper tract urothelial carcinoma (UTUC) is limited by invasiveness and sensitivity. There is an urgent need for noninvasive detection tool. We previ...
Unmet needs in penile cancer: Review and perspectives from the Global Society of Rare Genitourinary Tumors [0.03%]
阴茎癌的未满足需求:来自全球罕见生殖泌尿系统肿瘤学会的观点和展望
Luis G Medina,Salvador Jaime-Casas,Federico Eskenazi et al.
Luis G Medina et al.
Penile cancer is an uncommon yet aggressive disease, especially at advanced stages. Management can be morbid, and patients often face a significant psychosocial impact alongside a lack of patient advocacy/support system in most parts of the...
Peter S Palencia,Brandon L Ward,Maximilian J Rabil et al.
Peter S Palencia et al.
Background: Cystectomy is a potentially morbid procedure that presents a prime opportunity for quality improvement. We hypothesized that a novel electronic medical record (EMR)-based automated algorithm would demonstrate ...
Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer [0.03%]
与序贯吉西他滨和多西他赛相比,膀胱内灌注吉西他滨治疗高危非肌层浸润性膀胱癌的疗效比较
Jacob A Moyer,Mahnoor Ashraf,Lanyu Mi et al.
Jacob A Moyer et al.
Background: Sequential intravesical gemcitabine and docetaxel (Gem/Doce) are increasingly used for nonmuscle-invasive bladder cancer (NMIBC), especially in the setting of Bacillus Calmette-Guérin (BCG) shortage or failur...
Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma [0.03%]
尺寸重要吗?一项关于辅助免疫治疗接受模式及肿瘤尺寸依赖性生存率的国家分析:pT3N0M0期透明细胞肾细胞癌患者的规模与预后关系研究
Ethan Wan,Aditya Sathe,Charles C Peyton et al.
Ethan Wan et al.
Introduction: In November 2021, the US FDA approved pembrolizumab in the adjuvant setting for surgically resected clear cell renal cell carcinoma (ccRCC) at high-risk of recurrence, including small pT3a tumors. We hypothe...